Key Highlights

  • Telix Pharmaceuticals (ASX:TLX) reported H1 2026 Revenue of US$477 million, up 22% year on year, with gross Margin increasing to 55%.
  • Adjusted EBITDA rose 146% to US$52 million, while profit after tax was US$38 million compared with a US$2 million loss in H1 2025.
  • Precision Medicine revenue increased 27%, while the segment's adjusted EBITDA rose 26% to US$132 million.
  • Telix shares were trading at $17.10 on 20 August 2026, up 26 cents, or 1.54%, during the session.

Telix Pharmaceuticals (ASX:TLX) delivered revenue of US$477 million for the six months ended 30 June 2026, representing a 22% increase from US$390 million in H1 2025. Its shares were trading at $17.10 on 20 August 2026, up 26 cents, or 1.54%, at 11:29 am.

The company's gross margin increased to 55% from 53%, while Precision Medicine gross margin rose to 65% from 64%. Telix attributed the margin movement to product mix, commercial performance and operational efficiencies.

Adjusted EBITDA increased 146% to US$52 million from US$21 million. The measure benefited from commercial Demand across the product portfolio and a US$40 million non-refundable payment received under the company's collaboration with Regeneron.

Telix recorded profit after tax of US$38 million, compared with a US$2 million loss in H1 2025. Finance costs remained at US$19 million, while Research and Development expenditure increased to US$124 million from US$82 million.

Precision Medicine Drives Segment Growth

Telix's Precision Medicine segment remained the main contributor to commercial growth. Revenue increased 27% year on year, supported by higher sales volumes and Market Share gains from Illuccix and Gozellix.

Segment adjusted EBITDA increased 26% to US$132 million, while the segment gross margin reached 65%. The company also reported progress across several regulatory and clinical programs.

The Phase 3 BiPASS study of Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting was nearing completion of patient enrolment. The Illuccix Japan Phase 3 registrational study also completed enrolment.

For TLX101-Px, the FDA has set a September 11, 2026 PDUFA goal date for Pixclara. The European Marketing application for Pixlumi has also been accepted for review. Telix continues to work toward resubmission of the US application for TLX250-Px following a corrected Complete Response Letter.

R&D Investment Expands Late-Stage Pipeline

Telix invested US$124 million in R&D during the half, including US$68 million directed toward its therapeutics pipeline. The company reported several advances across late-stage programs.

TLX591-Tx progressed toward Part 2 of the ProstACT Global study after the FDA confirmed that Part 1 safety data was sufficient to support progression. Other developments included completion of enrolment in the OPTIMAL-PSMA Phase 2 study of TLX597-Tx and first patient dosing in the OPTIMAL-e study.

Telix also dosed the first patient in the LUTEON pivotal trial of TLX250-Tx and enrolled the first patient cohort in the IPAX BrIGHT pivotal study of TLX101-Tx for recurrent glioblastoma.

Manufacturing Investment Weighs on Segment Earnings

Telix Manufacturing Solutions reported total segment revenue of US$146 million, including US$89 million from third-party product sales and service fees and US$58 million of internal revenue.

However, the segment recorded an adjusted EBITDA loss of US$23 million, compared with a US$13 million loss in H1 2025. The wider loss reflected increased investment in Supply chain and logistics infrastructure.

The company continued expanding its manufacturing footprint, including facilities and operations across Australia, the United States, Belgium and Japan. These investments are intended to support commercial demand and future therapeutic programs.

FY26 Revenue and Other Income Expected Above US$1 Billion

Telix expects FY26 revenue and other income to exceed US$1 billion. Revenue remains on track toward the upper end of its existing US$950 million to US$970 million guidance range, alongside the US$40 million Regeneron payment.

R&D expenditure guidance remains at US$230 million to US$270 million. Telix ended June with US$252 million in cash and generated US$23 million in operating cash flow.

The company also established an at-the-market Facility that could allow it to issue new shares through American Depository Shares on Nasdaq, subject to applicable requirements and the filing of a prospectus supplement.

Conclusion

Telix's first-half FY26 results show continued commercial expansion, with revenue rising 22%, gross margin improving and adjusted EBITDA increasing sharply. The return to a US$38 million profit after tax compares with a US$2 million loss in the prior corresponding period, although the result includes the US$40 million Regeneron payment and higher R&D spending. Precision Medicine remains the principal Earnings contributor, while manufacturing investment is producing a larger segment EBITDA loss as the company expands infrastructure. With FY26 revenue and other income expected to exceed US$1 billion, the second half will include further regulatory milestones, clinical development activity and integration of the company's expanding commercial and manufacturing operations.